RSV Immunization Campaign for Infants & High-Risk Children – Glen Gower
Summary of Ontario’s Respiratory Virus Prevention Program (VRS) for Infants & pregnant People
This document outlines Ontario’s program to protect infants from Respiratory Syncytial Virus (RSV) using two main methods: BeyfortusMD (monoclonal antibody) and AbrysvoMC (prenatal vaccine).
Key Points:
* BeyfortusMD (for Infants): The preferred method for infant protection.
* Eligibility:
* Infants born on or after April 1st, 2025, and under 8 months old during the RSV season (Nov-April).
* Infants under 8 months born before the RSV season – consult a healthcare provider. SPO (Specialized Pediatric Outreach) offers it to those without a regular provider via the ”Children Above All” clinic.
* Children 24 months or less with high-risk conditions (see list below).
* High-Risk Conditions for BeyfortusMD:
* Chronic lung disease of prematurity (including bronchopulmonary dysplasia)
* Significant congenital heart disease
* Severe immunodeficiency
* Down Syndrome (Trisomy 21)
* Cystic fibrosis with respiratory involvement/growth retardation
* Neuromuscular disease
* Serious congenital respiratory tract anomalies
* Administration: Pediatricians, primary care providers, hospitals, and ambulatory clinics. SPO does not administer BeyfortusMD to high-risk children.
* AbrysvoMC (for Pregnant People):
* Eligibility: Pregnant people between 32-36 weeks gestation, expecting to deliver during the RSV season (Nov-April), after consulting their healthcare provider.
* Administration: Not offered in SPO clinics.
* Recommendation: Monoclonal antibody administration to the infant is the recommended approach. using both products isn’t expected to provide extra benefit.
* Timing: Both programs begin October 1st. the RSV season is generally November to April.
In essence, the program prioritizes giving infants direct protection via BeyfortusMD, while offering a prenatal option (AbrysvoMC) for pregnant people.